Last weekend, from August 28 to 31, the European Society of Cardiology (ESC) held its annual congress in Munich. For the biotech industry, ESC 2026 delivered a mixed bag: a cardiac myosin inhibitor opening a patient population with no approved therapies, long-term validation for its main competitor, a gene silencer stumbling in ATTR-CM countered by an siRNA triumph in severe hypertriglyceridemia, and GLP-1 drugs quietly earning a place in the new heart failure guidelines. Here are the five stories that mattered most.
By Coolcaesar - wikipedia.org